0.00001). However, the proportion of patients who underwent resection following PVE was 97% in TIPE and 88% PTPE, respectively (P ϭ Ͻ0.00001). Although there was no significant difference in patients who had major complications post-PVE, the rate for minor complications was significantly higher among patients who had PTPE (53.6% vs. 0%, P ϭ Ͻ0.0001). Conclusion: PVE is a safe and effective procedure in inducing liver hypertrophy to prevent postresection liver failure due to insufficient liver remnant.
(Ann Surg 2008;247: 49 -57) T o prevent posthepatectomy liver insufficiency, preoperative portal vein embolization (PVE) was introduced by Kinoshita et al in 1986. 1 The basic principle involved occluding a branch of portal venous flow, which subsequently leads to an ipsilateral hepatic atrophy and compensatory contralateral hypertrophy. Makuuchi et al first introduced this concept to clinical practice routinely in patients with cholestatic liver disease, chronic hepatitis, or cirrhosis to increase the number of patients suitable for curative surgery. 2 Currently, the indication for PVE has been extended to any major resection requiring preoperative manipulation to increase remnant liver volume. 3 Resection of hepatic tumors currently remains the gold standard treatment for patients with either primary or secondary liver malignancies, providing the only chance of longterm survival. In up to 45% of primary and secondary liver tumors, an extended hepatectomy is necessary to achieve clear resection margins (a major determinant of long-term survival). However, the rate of liver failure is high without preoperative manipulation of liver volume to prevent this. PVE would seem to be an ideal method used preoperatively for induction of hypertrophy of remnant liver to avoid postresection hepatic insufficiency. 1, 2 In patients with liver tumors, fewer than 20% are suitable for surgical resection. One of the major reasons for unresectability is that the remnant liver is of insufficient volume to support postoperative liver function. Furthermore, postoperative liver failure is still the principal cause of death following a major liver resection. It has been demonstrated that liver failure is directly related to the amount of liver remnant of functional volume. 4 Various procedures have been developed to produce liver regeneration. PVE has shown to reduce the risk of postoperative liver failure after major hepatectomy and increase the number of resectable patients. 5 However, controversy remains as to whether PVE only induces volume change rather than functional gain. The current study meta-analyzed all published articles on PVE to assess both the volumetric change and rate of liver failure after major liver resection following PVE to examine the impact of PVE on liver resection.
MATERIALS AND METHODS

Study Selection
A search of the published studies on portal vein embolization was carried out using a PubMed search covering Medline, Embase, Ovid, and Cochrane databases. Publications from 1990 to December 2005 were reviewed and the following "MeSH" search headings were used: "portal vein embolization", "liver regeneration", "liver resection", and "liver tumor". The above terms and their combinations were also searched as text-words. The "related articles" function was used to broaden the search, and all abstracts, studies, and citations retrieved were reviewed. References of the articles acquired were also included.
Inclusion Criteria
To be included in the analysis, studies had to: (1) be a human study; (2) clearly report the indications for surgery, and (3) be written in English.
Exclusion Criteria
Studies were excluded from the analysis if: (1) studies had failed to describe the method and material for PVE; (2) the outcomes and parameters of interest were not clearly reported; (eg, studies that did not record future liver remnant ͓FLR͔ before and after PVE and the percentage of hypertrophy ratio were excluded) (3) it was impossible to extract the appropriate data from the published results or (4) if there was overlap between authors, centers, or patient cohorts evaluated in the published literature. A flow chart of literature search strategies is illustrated in Figure 1 . For presentation purposes, complications are subdivided into "minor" or "major" complication based on the revised 2004 Clavien Classification 6,7 , Clavien's Grade I and II as "minor"; any Grade III and above as "major" complications.
Parameters and Outcomes of Interest
Statistical Analysis
Statistical analysis was carried using SPSS for Windows (version12.0, SPSS Inc. Chicago, IL). Results are expressed as mean Ϯ SD unless otherwise indicated. Comparisons between categorical variables were analyzed using the 2 test.
The meta-analysis was performed in line with recommendations from the Cochrane Collaboration and the Quality of Reporting of Meta-analyses (QUORUM) guidelines. 8, 9 Statistical analysis of dichotomous variables was carried out using odds ratio (OR) as the summary statistic. Volumetric change and rate of complications after PVE were analyzed. Both were reported with 95% confidence intervals (CI). An odds ratio of less than 1 favored the PVE and the point estimate of the odds ratio was considered to be statistically significant at the P Ͻ 0.05 level if the 95% confidence interval did not include the value 1. In the tabulation of the results, squares indicate the point estimates of the treatment effect (OR, weighted mean difference ͓WMD͔) with 95% confidence intervals indicated by horizontal bars. The diamond represents the summary estimate from the pooled studies with 95% confidence intervals.
The Mantel-Haenszel method was used to combine the odds ratio for the outcomes of interest using a "random effect" meta-analytical technique. Both increase in volume remnant, and percentage of embolized patients who underwent resection following PVE were analyzed. Heterogeneity was assessed by graphical exploration with funnel plots to evaluate publication bias. 10, 11 
RESULTS
A total of 198 publications were identified ( Fig. 1 ). Of these, only 37 consisting of 1088 patients met our inclusion criteria, which included patients with hepatocellular carcinoma (HCC, n ϭ 265), liver metastases (n ϭ 393) and cholangiocarcinoma (n ϭ 430) ( Table 1 ). The remaining articles were excluded most commonly because either the FLR was not reported or the study included a mixture of portal vein embolization and arterial chemoembolization cases.
PVE was performed using either transileocolic portal vein embolization (TIPE) or percutaneous transhepatic portal vein embolization (PTPE). Technique was dependent on either the preference of the interventional radiologist or the availablility of facilities at each hospital. The procedure was well tolerated by all patients. The overall morbidity rate for PVE was 2.2% without mortality. The complications were divided into major and minor ( Table 2) . Two patients required re-embolization 12,13 because of the technical failure.
Following PVE, 930 (85%) patients underwent laparotomy for attempted major hepatectomy. However, in 158 patients (17%), resection was not possible. These included 27 patients in whom liver resection was abandoned at laparotomy due to intraoperative finding of peritoneal dissemination (n ϭ 15), tumor extension precluding curative resection (n ϭ 9), portal node metastases (n ϭ 2), and tumor invasion to hepatic artery and portal vein (n ϭ 1). The reasons for the remaining 131 patients who did not undergo the planned laparotomy were inadequate hypertrophy of the future remnant liver (n ϭ 18), severe progression of liver metastases (n ϭ 43), development of pulmonary metastases or extrahepatic spread (n ϭ 35), patient's refusal of operation (n ϭ 1), remission of disease or treatment with chemotherapy (n ϭ 25), a poor general condition, unfit for operation (n ϭ 1), and other unspecified reasons (n ϭ 8).
Following resection, the overall morbidity and mortality rates were 16% and 1.7%, respectively (Table 3) . Changes in liver function detected biochemically after PVE were minor and transient. When transaminase levels rose, they peaked at a level less than 3 times baseline from 1 to 3 days post-PVE. They then returned to normal after 7 to 10 days. Prothrombin time was rarely affected. One patient developed cholangitis following PTPE as a result of inadvertent puncture and injection of contrast into a segmental bile duct, which was already obstructed by hilar cholangiocarcinoma.
The cholangitis subsided within a few days following conservative treatment with a broad-spectrum antibiotic. 14 One patient developed main and left portal vein (PV) thrombosis after embolization diagnosed on follow-up computerized tomography (CT). This was evident clinically as a low-grade fever and the thrombosis was treated successfully with a 30-hour infusion of recombinant tissue plasminogen activator and mechanical thrombolysis. 15 One patient developed liver necrosis following damage to a branch of hepatic artery. This was managed with percutaneous drainage of the ensuing abscess. This patient subsequently made a full recovery but later refused liver resection. Following resection, 23 patients The meta-analysis demonstrated an overall increase in liver volume following PVE, independent of technique (Fig.  2) . The number of patients who underwent liver resection after PVE was also high ( Fig. 3 ). When the 2 techniques (PTPE vs. TIPE) used for PVE were compared, the increase in remnant liver volume was higher in the PTPE group (11.9 vs. 9.7%, P ϭ 0.00001). However, the relative number of patients undergoing resection following PVE was higher in the TIPE group than in the PTPE group (97 vs. 88%, P ϭ Ͻ0.00001). Minor complications were significantly higher in the PTPE than TIPE group (53.6 vs. 0%, P ϭ Ͻ0.0001). There was no significant difference for major complications (P ϭ 0.33, Fig. 4 ).
DISCUSSION
Preoperative portal vein embolization has been used clinically to induce hypertrophy of the contralateral lobe and prevent postoperative liver failure as a result of insufficient remnant liver reserve following resection. However, the results reported for portal vein embolization are mainly based on individual series. To our knowledge, there have been no properly constructed studies or randomized trials examining the effectiveness of portal vein embolization on liver regeneration or its impact on liver resection. The current study examined a total of 1088 patients from 37 published series in 2, 14, 26, 30, 37, 38, 40, 43, 45, 45 304 (28) Embolization materials Cyanoacrylate ϩ lipidol 3, 22, 29, 36, 47, 48 169 Gelfoam ϩ thrombin ϩ urografin 26, 30, 31, 42, 45 309 PVA ϩ coil ϩ lipidol ϩ fibrin glue 12, 25, 34 66 Fibrin glue ϩ lipidol ϩ PVA 14, 18, 21, 24, 32, 41, 44, 46 80 Gelfoam ϩ urografin ϩ gentamicin 2, 37, 39, 40, 43 123 Embol-78 33 51 Gelfoam ϩ coils 13, 20, 28, 35, 49 137 PVA ϩ micro coils 5, 15, 23, 47 153 
TABLE 2. Complications Following Portal Vein Embolization
Details
No.
Minor complications
Abdominal discomfort or pain 2,12,32-36,48 209 Fever 2, 12, 26, [31] [32] [33] [34] 36, [46] [47] [48] 250 Nausea or vomiting 32, 34 26 Ileus 26, 31 9 Overflow of embolization materials 31 2 Coil displacement 23 1 Major complications Liver abscess 39 3 Cholangitis 14, 39 2 Main or left portal vein thrombosis 15, 23 2 Subscapular hematoma 23 2 Portal hypertension 23 1 Septic necrosis from hepatic artery injury 3 1 Morbidity  148  Transient liver failure 2,12,15,21-24,36,44,48,49 23 Pleural effusion 13, 22, 36, 48 38 Bile leak 15, [23] [24] [25] 38, 47, 48 16 Liver or subphrenic abscess 2,15,22-24,37-39, 43 11 Ileus 48 7 Ascites 12,13,22, 36 7 Transient or prolonged jaundice 12, 20 6 Renal failure 12, 22, 25, 39 6 Wound infection 23, 37 5 UTI 36, 48 5 Respiratory complications 37,39, 48 3 Biliary fistula Without surgical intervention but percutaneous drainage 3,34,36
5
With surgical intervention, re-laparotomy 34 5 Hepatitis 2, 39 3 Abdominal hemorrhage 22, 48 2 Small bowel perforation 15, 23 2 Phelibitis 36 1 Pancreatitis 28 1 Multiorgan failure 39 1 Pancreatic leak 43 1 Mortality 16 Acute liver failure 3,20,31, 47 7 Portal vein thrombosis 25, 29, 36 3 Severe sepsis causing massive intra-abdominal hemorrhage 23 2 Cholangitis 2,37 2 Cardiac failure 31, 45 1 MRSA infection 36 English language. Patients underwent portal vein embolization with an intention to operate. Using meta-analysis, preoperative portal vein embolization has been shown to significantly increase the future remnant liver volume making more patients suitable for liver resection. Two different methods have been reported to access the portal vein for embolization: transileocolic portal embolization (TIPE) and percutaneous transhepatic portal embolization (PTPE). 2 When analyzed, both approaches produced an overall increase in liver volume with a high proportion of patients undergoing liver resection as a result. Although PTPE would seem to be more effective in increasing remnant liver volume when compared with TIPE, the relative number of patients who underwent resection following PVE was higher in the TIPE group. In TIPE, a minilaparotomy is performed with the patient under general anesthesia to facilitate insertion of the catheter into the portal vein through a branch of the ileocolic vein. 2 A diagnostic laparoscopy and laparoscopic ultrasound scan performed during the procedure provides further accurate staging of the disease. This may explain why a larger proportion of patients underwent liver resection following PVE with this technique. This technique is preferred by many surgeons in Japan, China, and is often used when interventional radiologic facilities are not available for the percutaneous method. 18 -20 Open approach (TIPE) for portal vein embolization has recognizable disadvantages; for example, requiring a general anesthesia and the theoretical higher risk of postoperative complications. 2 The percutaneous access to the portal venous system can be performed in the interventional suite with the patient under local anesthesia and conscious sedation. Another advantage is that the technique is simple and safe without inducing adhesions or scarring at the hilum, which may otherwise render surgery more difficult. There is also no risk of general anesthesia, reduced cost, and recovery time. Indeed, the PTPE approach has become the standard tech-nique for PVE. 21, 22 However, the result from meta-analysis showed that the rate of minor complications was significantly lower in the TIPE group when compared with the percutaneous group, but no significant differences were noted for major complications.
PTPE can be performed by either of two standard approaches: the transhepatic ipsilateral 15, 23 and transhepatic contralateral. 1 The advantage of transhepatic ipsilateral approach is that the future liver remnant is not instrumented, minimizing the risk of portal vein thrombosis and contralateral vascular injury to the FLR. Disadvantages of this approach include difficulty in catheterization. The acute angulation between right portal branches necessitates use of a reverse-curved catheter and can result in nontarget embolization from displacement of embolization materials on removal of catheter. The major benefit of transhepatic contralateral approach is that catheterization of the desired right portal vein branches is more direct via the left system. The major disadvantage is of the possible inadvertent damage to the vascular tree of future liver remnant. However, this meta-analysis revealed no significant difference in complications related to the 2 types of percutaneous approaches.
Many commercially available embolic agents have been used for preoperative PVE without significant differences in degrees or rates of hypertrophy of the nonembolized segments. 5 The ideal agent is well tolerated by the patient and causes permanent embolization of the portal vein and its branches with minimal risk of recanalization. In addition, it should be widely available and easily administered without causing inflammatory reaction and be associated with a low risk of postembolization syndrome and hepatic necrosis. The commonest embolization materials used include a combination of gelfoam, thrombin and urografin, cyanoacrylate and lipidiol, polyvinyl alcohol (PVA) and microcoil, gelfoam and coils or gelfoam, urografin, and gentamicin, respectively. PVA is safe, easy to use, and produces minimal inflammation and creates durable portal vein occlusion when used in combination with metal coils. 23 PVA, microspheres, or gelfoam appear to provide occlusion to small out flow vessels in the tumor bearing segments, while the metal coils provide large vessels inflow occlusion. This accounts for more permanent occlusion associated with the combination of coils and PVA. Portal vein embolization with absolute ethanol may be particularly useful treating patients with HCC because the hypertrophy that is induced with this material has been shown to be greater than that produced with other embolic substances. 15 However, portal vein embolization with alcohol can produce significant peripheral fibrosis and necrosis, and severe pain. The damage to the liver parenchyma and bile duct could even increase risk of subsequent biliary cancer. 24 De Baere et al advocated cyanoacrylate as the best substance for portal vein embolization because it leads to fast and reliable hypertrophy of FLR, thereby minimizing the delay to definitive resection. Cyanoacrylate produces reliable portal vein occlusion, which persists for 4 weeks after portal vein embolization, whereas gelfoam and thrombin may produce only transient portal vein embolization with recanalization of the vessels reported. 12 Cyanoacrylate embolization produces a 90% increase in volume of the FLR after 30 days compared with a 35% increase in volume after 43 days in cases where gelatin and thrombin were used. However, a marked inflammatory reaction involving peribiliary fibrosis and casting of the portal vein was noted with cyanoacrylate, making the subsequent surgical procedure more difficult. 25, 26 Although each of the embolic agents has advantages and disadvantages, no single agent has been proven to be consistently superior. All patients underwent a volumetric assessment of their liver volumes both before PVE and surgery using CT imaging. Postembolization CT is essential for assessment of liver volume change and planning of liver resection. 5 The average interval for the CT volumetric study from portal vein embolization to surgery was 29 days. CT is used to make direct measurements of total liver volume, volume to be resected, and volume of the future liver remnant. The future liver remnant volume is considered to be the volume of the liver segments (I-IV, eg, the volume of segments I, II, and III in a patient undergoing an extended right liver resection). Several methods are available to measure or calculate the future liver remnant volume. This can be measured directly on CT then divided by a total estimated liver volume: FLR volume ϭ (remnant liver volume ϫ 100)/(total liver volume Ϫ tumor volume). 27 The increase in FLR volume after portal vein embolization can be calculated with the following formula: (volume of the FLR before surgery Ϫ volume of the FLR before PVE) ϫ 100/(volume of the FLR before PVE). The increase in the %FLR after portal vein embolization can also be calculated from: (%FLR after PVE Ϫ %FLR before surgery). 27 The total liver volume can be estimated on the basis of the body surface area using the formula; total liver volume ϭ 706.2 ϫ body surface area ϩ2.4. 28 The calculated range of percentage increase of future liver remnant volume following portal vein embolization was 8% to 27% in our analysis. The future liver remnant estimated preoperatively is the major determinant factor for a preoperative portal vein embolization in addition to the clinical consideration of presence or absence of chronic liver disease. Capussotti et al proposed performing preoperative portal vein embolization for patients undergoing major liver resection if the future liver remnant estimated was less than 25% in patients with a normal liver and 30% in those with abnormal or diseased liver. 29 Hence, FLR volume is used as a surrogate for altered risk of postoperative liver failure. This rationale is based on data indicating that the increase in FLR volume following PVE is associated with improvement in function. 16, 17 Little evidence exists in literature, correlating the quantitative liver function with the future remnant liver volume.
Although a number of complications have been reported, complications are infrequent after portal vein embolization, and there was no mortality directly related to the procedure (Table 2) . Indications for portal vein embolization are important. Currently, 4 factors are important to decide when and whether to conduct portal vein embolization. Firstly, the ratio of future liver remnant and total estimated liver volume (TELV) should be enumerated. Secondly, patients need to be classified according to those with normal hepatic parenchyma and those with underlying liver diseases such as, cholestasis, acute or chronic inflammation, steatosis, fibrosis, or cirrhosis because these factors will contribute to how much future liver remnant is needed to decrease postoperative complications and liver failure. The lowest absolute liver volume needed to support postresection hepatic function has not been clearly identified. However, in patients with normal liver parenchyma, preservation of a perfused section of liver that comprises 25% of the total hepatic volume is usually sufficient to prevent major postoperative morbidity and mortality. This 25% value has been determined empirically, and there is a paucity of data regarding the exact volume of liver that can be resected safely without postoperative liver insufficiency when the remaining hepatic parenchyma is completely normal. 25 The functional capacity of liver that is compromised by cirrhosis, fibrosis, steatosis, or inflammation is variable. A large future liver remnant is required to avoid postoperative liver failure and insufficiency with diseased hepatic parenchyma. Two recent studies show that a ratio of at least 40% of FLR/TELV should remain to minimumize postoperative complications in patients who have chronic liver disease or who have received high-dose chemotherapy. 3, 27 When FLR/TELV ratios are below these levels, portal vein embolization may be preformed in an attempt to increase future liver remnant volume. Farges et al in a prospective nonrandomized study demonstrated significantly increased postoperative complications in those with chronic liver disease undergoing right hepatectomy with no preoperative PVE. In particular, when comparing PVE versus no PVE (n ϭ 14 vs. 14, respectively) significant differences included patients with one or more complications (7 vs. 13, P ϭ 0.012), with pulmonary complications (4 vs. 13, P ϭ 0.0007), with liver failure (1 vs. 7, P ϭ 0.01), stay in the intensive care unit (ICU) (5 vs. 12, P ϭ 0.002), and inpatient stay (13 vs. 30, P ϭ 0.00002). 22 In addition to preoperative PVE, patients with underlying liver disease might also require a careful assessment of functional hepatic reserve before and after PVE to assess the risk of postoperative liver failure. Thirdly, the presence of systemic disease for example diabetes mellitus may limit hepatic hypertrophy. Insulin is a comitogen with hepatocyte growth factor, which often causes faster rates of regeneration. Fourthly, planning for the extent of combined surgical procedures (eg, right liver resection and pancreaticoduodenectomy) is very important because more functional hepatic reserve may be required to reduce postoperative morbidity.
In conclusion, portal vein embolization has been increasingly used during recent years with minimal side effects to facilitate major liver resection making more patients suitable for liver resection. This should be considered for any patient with a small future remnant liver volume. Limitations. Meta-analysis has a potential weakness of bias introduced by selection and location of studies. Authors might be more likely to report positive findings in an international, English language journal and negative findings in a local journal, and studies with significant results are more likely to get published than those with nonsignificant results. A randomized, control trial is needed to answer questions related to the effectiveness of PVE on liver regeneration and to identify those who would benefit from such intervention preoperatively.
